The role of liver biopsy to assess non-alcoholic fatty liver disease

Reviews on Recent Clinical Trials

Volumn 9, Issue 3, 2014, Pages 159-169

  Kobyliak, Nazarii ^a   Abenavoli, Ludovico ^b  

^a BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Complications; Histological features; Intra inter observer variability; Liver biopsy; Non alcoholic fatty liver disesase; Non alcoholic steatohepatitis; Sampling variability

Indexed keywords

ARTICLE; BACTEREMIA; BARIATRIC SURGERY; BILIARY PERITONITIS; BILIARY TRACT HEMORRHAGE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; HEMATOTHORAX; HEMOPERITONEUM; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; IRON DEPOSITION; IRON METABOLISM; LIPOGRANULOMA; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER HEMATOMA; LOBULAR INFLAMMATION; NONALCOHOLIC FATTY LIVER; PAIN; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAGING; STEATOSIS; VISCERAL PERFORATION; ADVERSE EFFECTS; LABORATORY DIAGNOSIS; LIVER; NEEDLE BIOPSY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

BIOPSY, NEEDLE; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX; SPECIMEN HANDLING;

EID: 84922282260     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666141216102231     Document Type: Article

References (122)

1. [1] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
2. [2] Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British society of gastroenterology. Gut 1999; 45: 1-11.
3. [3] Rockey DC, Caldwell SH, Goodman ZD, et al. Liver Biopsy. Hepatol 2009; 49: 1017-44.
4. [4] Piekarska A. Principles of the Biopsy Procedure. In: Liver Biopsy, Dr Hirokazu Takahashi (Ed.). InTech 2011; pp. 25-32.
5. [5] Wieckowska A, Feldstein AE. Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive. Semin Liver Dis 2008; 28: 386-95.
6. [6] Farrell GC, CZ Larter. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatol 2006; 43: 99-112.
7. [7] Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities?. Curr Hepatol Rep 2014; 13: 151-8.
8. [8] Bettermann K, Hohensee T, Haybaeck. Steatosis and steatohepatitis: complex disorders. J. Int J Mol Sci 2014; 15: 9924-44.
9. [9] Tiniakos CH, Kittas D. Pathology of nonalcoholic fatty liver disease. Ann Gastroenterol 2005; 18: 148-59.
10. [10] Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7392-402.
11. [11] Nascimbeni F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013: 59; 859-71.
12. [12] Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Compar Hepatol 2004; 3: 8.
13. [13] Skripenova S, Trainer TD, Krawitt EL, et al. Variability of grade and stage in simultaneously paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007; 60: 321-4.
14. [14] Standish RA, Cholongitas E, Dhillon A, et al. An appraisal of the histopatological assessment of liver fibrosis. Gut 2006; 55: 569-78.
15. [15] Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-73.
16. [16] McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterol 1990; 99: 1396-400.
17. [17] Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
18. [18] Froehlich F, Lamy O, Fried M, et al. Practice and complications of liver biopsy. Results of a nationwide survey in switzerland. Dig Dis Sci 1993; 38: 1480-4.
19. [19] Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, Methods, and Outcomes of Percutaneous Liver Biopsy in England and Wales: An Audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41.
20. [20] Mayoral W, Lewis JH. Percutaneous Liver Biopsy: What Is the Current Approach? Results of a Questionnaire Survey. Dig Dis Sci 2001; 46: 118-27.
21. [21] Cadranel JF, Rufat P, Degos F. Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey. For the Group of Epidemiology of the French Association for the Study of the Liver (Afef). Hepatol 2000;32: 477-81.
22. [22] Al Knawy B, Shiffman M. Percutaneous Liver Biopsy in Clinical Practice. Liver Int 2007; 27: 1166-73.
23. [23] Eisenberg E, Konopniki M, Veitsman E, et al. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anaesth Analg 2003; 96: 1392-6.
24. [24] Castera L, Negre I, Samii K, Buffet C. Pain experienced during Percutaneous liver biopsy. Hepatol 1999; 30:1529-30.
25. [25] Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993; 118: 96-8.
26. [26] Siegel CA, Silas AW, Suriawinata AA, et al. Liver biopsy 2005: When and how? Cleve Clin J Med 2005; 72:199-224.
27. [27] Minuk GY, Sutherland LR, Wiseman DA, et al. Prospective study of the incidence of ultrasound detected intrahepatic and subcapsular haematoma in patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy. Gastroenetrol 1987; 92: 290-3.
28. [28] Sugano S, Sumino Y, Hatori T, et al. Incidence of ultrasound detected intrahepatic haematoma due to trucut needle liver biopsy. Dig Dis Sci 1991; 36: 1229-33.
29. [29] Chuah SY. Liver Biopsy--Past, Present and Future. Singapore Med J 1996; 37: 86-90.
30. [30] Lichtenstein DR, Kim D, Chopra S. Delayed massive hemobilia following percutaneous liver biopsy: treatment by embolotherapy. Am J Gastroenterol 1992; 87: 1833-8.
31. [31] Abdullah Saeed Gozai Al-Ghamdi. Complications of Liver Biopsy. In: Liver Biopsy, Dr Hirokazu Takahashi (Ed.). InTech 2011; pp. 363-70.
32. [32] Ahluwalia JP, LaBrecque DR. A large bilioma causing gastric outlet obstruction after a percutaneous liver biopsy. J Clin Gastroenterol 2004; 38: 535-9.
33. [33] Lublin M, Danforth DN. Iatrogenic gall bladder perforation: conservative management by percutaneous drainage and cholecystectomy. Am Surg 2001; 67: 760-3.
34. [34] Myers R P, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy; a population based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
35. [35] van der Poorten D, Kwok A, Lam T, et al. Twenty-Year Audit of Percutaneous Liver Biopsy in a Major Australian Teaching Hospital. Intern Med J 2006; 36: 692-9.
36. [36] Brunt EM. Do you see what I see? The role of quality histopathology in scientific study. Hepatol 2008; 47:771-4.
37. [37] Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.
38. [38] Miette V, Abdennour M, Sandrin L, Sasso M. Metabolic Steatosis & Fibrosis: Review of the Non -Invasive Tools for Diagnosis and Screening. In: Liver Biopsy in Modern Medicine, ed. Y. Mizuguchi. InTech 2011; pp. 36-62.
39. [39] Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatol 2006; 44: 874-80.
40. [40] Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterol 2005; 128: 1898-906.
41. [41] Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 481-6.
42. [42] Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
43. [43] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatol 2003; 38: 1449-57.
44. [44] Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-5.
45. [45] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatol 2005; 41: 1313-21.
46. [46] Fukusato T, Fukushima J, Shiga J, et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 122-7.
47. [47] Gawrieh S, Knoedler DM, Saeian K, et al. Effects of interventions on intraand interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol 2011; 15: 19-24.
48. [48] El-Badry AM, Breitenstein S, Jochum W, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-7.
49. [49] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatol 2004; 40: 1387-95.
50. [50] Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011; 52: 593-617.
51. [51] Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Liver Dis 1998; 15: 246-58.
52. [52] Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 691-707.
53. [53] Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008; 48: 829-34.
54. [54] Baldridge AD, Perez-Atayde AR, Graeme-Cook F, et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127: 700-4.
55. [55] Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. J Pathol 1988; 156: 155-60.
56. [56] Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatol 2005; 42: 641-9.
57. [57] Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13.
58. [58] Patton HM, Yates K, Unalp-Arida A. Association between metabolic syndrome and liver histology among children with nonalcoholic fatty liver disease. Am J Gastroenterol 2010; 105: 2093-102.
59. [59] Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatol 2009; 50: 1113-20.
60. [60] Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
61. [61] Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16: 49-56.
62. [62] Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98: 2064-71.
63. [63] Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improvement in nonoalcholic steatohepatitis following 48 weeks of treatment with the PPARligand rosiglitazone. Hepatol 2003; 38: 1008-17.
64. [64] Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135: 48-58.
65. [65] Barker KB, Palekar NA, Bowers SP, et al. Nonalcoholic steatohepatitis: effect of roux-en-y gastric bypass surgery. Am J Gastroenterol 2006; 101: 368-73.
66. [66] Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD clinico-pathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatol 2009: 49: 809-20.
67. [67] Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560-5.
68. [68] Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterol 1994; 107: 1103-9.
69. [69] Scheuer PJ, Lefkowitch JH. Liver biopsy interpretation. 7th ed. Elsevier Sanders, 2006.
70. [70] Zhu H, Bodenheimer HCJ, Clain DJ, et al. Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease. World J Gastroenterol 2010; 16: 5065-9.
71. [71] Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3-16.
72. [72] Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterol 1999; 116: 1413-9.
73. [73] Mallory F. Cirrhosis of the liver. Five different types of lesions fro m which it may arise. Bul. Johns Hopkins Hosp 1911; 22: 69-75.
74. [74] Zatloukal K, French SW, Stumptner C, et al. From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res 2007; 313: 2033-49.
75. [75] Denk H, Gschnait F, Wolff K. Hepatocellar hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest 1975; 32: 773-6.
76. [76] Stumptner C, Omary MB, Fickert P, et al. Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol 2000; 156: 77-90.
77. [77] Strnad P, Harada M, Siegel M, et al. Transglutaminase-2 regulates Mallory body inclusion formation and injury associated liver hypertrophy. Gastroenterology 2007; 132: 1515-26.
78. [78] Pei PJ, Danbara N, Tsujita-Kyutoku M, et al. Immunohistochemical profiles of Mallory body by a panel of anti-cytokeratin antibodies. Med Electron Microsc 2004; 37: 114-8.
79. [79] Riley NE, Li J, McPhaul LW, et al. Heat shock proteins are present in mallory bodies (cytokeratin aggresomes) in human liver biopsy specimens. Exp Mol Pathol 2003; 74: 168-72.
80. [80] Bjorkoy G, Lamark T, Brech A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171: 603-14.
81. [81] Okanoue T, Ohta M, Ou O, et al. Relationship of Mallory bodies to intermediate filaments in hepatocytes. A scanning electron microscopy study. Lab Invest 1985; 53: 534-40.
82. [82] Denk H, Franke WW, Eckerstorfer R, et al. Formation and involution of Mallory bodies (“alcoholic hyalin”) in murine and human liver revealed by immunofluorescence microscopy with antibodies to prekeratin, Proc Natl Acad Sci U S A 1979; 76: 4112-6.
83. [83] Denk H, Franke WW. Rearrangement of the hepatocyte cytoskeleton after toxic damage: involution, dispersal and peripheral accumulation of Mallory body material after drug withdrawal. Eur J Cell Biol 1981; 23: 241-9.
84. [84] Ray MB. Distribution patterns of cytokeratin antigen determinants in alcoholic and nonalcoholic liver diseases. Hum Pathol 1987; 18: 61-6.
85. [85] Powell EE, Cooksley WGE, Hanson R. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty two patients for up to 21 years. Hepatol 1990; 11: 74-80.
86. [86] Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterol 1988; 95: 1056-62.
87. [87] Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatol 1990; 12: 1106-10.
88. [88] Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. J Hepatol 2000; 32: 689-702.
89. [89] Müller T, Langner C, Fuchsbichler A, et al. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatol 2004; 39: 963-9.
90. [90] Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey). Hepatology 1994; 20: 1061-77.
91. [91] Jensen K, Gluud C. The Mallory body: theories on development and pathological significance (Part 2 of a literature survey). Hepatology 1994; 20: 1330-42.
92. [92] Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
93. [93] Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in NASH. J Hepatol 1999; 31: 430-4.
94. [94] Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterol 2001; 120: 1183-92.
95. [95] Chedid A, Mendenhall CL, Tosch T, et al. Significance of megamitochondria in alcoholic liver disease. Gastroenterol 1986; 90: 1858-64.
96. [96] Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson’s Disease. Gastroenterology 1968; 55: 354-62.
97. [97] Le TH, Caldwell SH, Redick JA, et al. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatol 2004; 39: 1423-9.
98. [98] Caldwell SH, Chang CY, Nakamoto RK, et al. Mitochondria in non-alcoholic fatty liver disease. Clin Liver Dis 2004; 8: 595-617.
99. [99] Cortez-Pinto H, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-9.
100. [100] Abraham S, Furth EE. Receiver operating characteristic analysis of glycogenated nuclei in liver biopsy specimens: quantitative evaluation of their relationship with diabetes and obesity. Hum Pathol 1994; 25: 1063-8.
101. [101] George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterol 1998; 114: 311-8.
102. [102] Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatol 2011; 53: 448-57.
103. [103] Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on nonalcoholic steato-hepatitis. J Hepatol 2009; 50: 351-7.
104. [104] Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterol 2010; 138: 905-12.
105. [105] Maliken BD, Nelson JE, Klintworth HM, et al. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatol 2013; 57: 1806-13.
106. [106] Washington K, Wright K, Shyr Y, et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000; 31: 822-8.
107. [107] Cortez-Pinto H, Baptista A, Camilo ME, et al. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepato-Gastroenterol 2001; 48: 87-90.
108. [108] Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of non-alcoholic fatty liver disease. Hepatol 2004; 40: 475-83.
109. [109] Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
110. [110] Fassio E, Alvarez E, Dominguez N, et al. Natural history of non-alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatol 2004; 40: 820-6.
111. [111] Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatol 1999; 29: 664-9.
112. [112] Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127-30.
113. [113] Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-60.
114. [114] Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in non-alcoholic steatohepatitis compared with hepatitis C. Hepatol 2003; 38: 420-7.
115. [115] Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesityrelated cryptogenic cirrhosis. Hepatol 2002; 35: 1485-93.
116. [116] Marrero J, Fontana R, Su G, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatol 2002; 36: 1349-54.
117. [117] Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatol 2000; 31: 241-6.
118. [118] Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
119. [119] Brunt EM, Kleiner DE, Wilson LA, et al. The NAS and the histopathologic diagnosis of NASH: distinct clinicopathologic meanings. Hepatol 2011; 53: 810-20.
120. [120] Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatol 2011; 54: 344-53.
121. [121] Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatol 2012; 56: 1751-9.
122. [122] Bedossa, P. And the FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; doi: 10.1002/hep.27173.